Importantly, we found Ki67 levels to be independent of PIK3CA mutation status or other alterations in the pathway, suggesting that selecting cohorts of patients based on pathway activation would not necessarily identify low risk patients with non-proliferative cancers. The gene discussed is PIK3CA; the disease is cancer.